Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
17
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Kush Arvind | Chief Financial Officer | 5 | $0 | $0 | 2024-02-26 |
| Moran Susan | Chief Medical Officer | 8 | $0 | $0 | 2024-02-26 |
| Oliger Christy J. | Director | 1 | $0 | $0 | 2024-02-26 |
| Van Hauwermeiren Timothy | Director | 2 | $0 | $0 | 2024-02-26 |
| Larson Yi | Director | 3 | $0 | $0 | 2024-02-26 |
| Katabi Maha | Director | 10 | $8.50M | $0 | 2024-02-26 |
| You Angie | Director | 2 | $0 | $0 | 2024-02-26 |
| Viking Global Opportunities GP LLC | 10% Owner | 2 | $0 | $0 | 2024-02-26 |
| Ott David C. | 10% Owner | 2 | $0 | $0 | 2024-02-26 |
| SONG KENNETH | President and Chief Executive | 5 | $0 | $0 | 2024-02-26 |
| Heyman Richard A. | Director | 1 | $0 | $0 | 2024-02-26 |
| TAGLIAFERRI MARY | Director | 2 | $0 | $0 | 2024-02-26 |
| Viking Global Opportunities Drawdown GP LLC | 10% Owner | 10 | $25.00M | $0 | 2023-09-19 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% Owner | 2 | $0 | $0 | 2023-09-19 |
| Redmile Biopharma Investments II, L.P. | 10% Owner | 6 | $0 | $0 | 2023-09-19 |
| Shabet Rose Sharon | 10% Owner | 10 | $25.00M | $0 | 2023-09-19 |
| Adelman Robert J | 10% Owner | 6 | $0 | $0 | 2023-09-19 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| SONG KENNETH | PRESIDENT AND CHIEF EXECUTIV | D To issuer deriv | 2024-02-26 | 2024-02-27 | 114,763 | — | $0 | 0 | SEC↗ |
| SONG KENNETH | PRESIDENT AND CHIEF EXECUTIV | D To issuer deriv | 2024-02-26 | 2024-02-27 | 480,000 | — | $0 | 0 | SEC↗ |
| SONG KENNETH | PRESIDENT AND CHIEF EXECUTIV | D To issuer deriv | 2024-02-26 | 2024-02-27 | 758,607 | — | $0 | 0 | SEC↗ |
| Kush Arvind | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2024-02-26 | 2024-02-27 | 301,745 | — | $0 | 0 | SEC↗ |
| Kush Arvind | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2024-02-26 | 2024-02-27 | 164,000 | — | $0 | 0 | SEC↗ |
| Kush Arvind | CHIEF FINANCIAL OFFICER | D To issuer deriv | 2024-02-26 | 2024-02-27 | 149,777 | — | $0 | 0 | SEC↗ |
| Moran Susan | CHIEF MEDICAL OFFICER | D To issuer deriv | 2024-02-26 | 2024-02-27 | 194,514 | — | $0 | 0 | SEC↗ |
| Moran Susan | CHIEF MEDICAL OFFICER | D To issuer deriv | 2024-02-26 | 2024-02-27 | 60,757 | — | $0 | 0 | SEC↗ |
| Moran Susan | CHIEF MEDICAL OFFICER | D To issuer deriv | 2024-02-26 | 2024-02-27 | 77,805 | — | $0 | 0 | SEC↗ |
| Moran Susan | CHIEF MEDICAL OFFICER | D To issuer deriv | 2024-02-26 | 2024-02-27 | 164,000 | — | $0 | 0 | SEC↗ |
| Katabi Maha | Director | D To issuer deriv | 2024-02-26 | 2024-02-27 | 18,235 | — | $0 | 0 | SEC↗ |
| Larson Yi | Director | D To issuer deriv | 2024-02-26 | 2024-02-27 | 40,848 | — | $0 | 0 | SEC↗ |
| Larson Yi | Director | D To issuer deriv | 2024-02-26 | 2024-02-27 | 59,399 | — | $0 | 0 | SEC↗ |
| Larson Yi | Director | D To issuer deriv | 2024-02-26 | 2024-02-27 | 14,332 | — | $0 | 0 | SEC↗ |
| TAGLIAFERRI MARY | Director | D To issuer deriv | 2024-02-26 | 2024-02-27 | 40,848 | — | $0 | 0 | SEC↗ |
| TAGLIAFERRI MARY | Director | D To issuer deriv | 2024-02-26 | 2024-02-27 | 73,731 | — | $0 | 0 | SEC↗ |
| Van Hauwermeiren Timothy | Director | D To issuer deriv | 2024-02-26 | 2024-02-27 | 48,628 | — | $0 | 0 | SEC↗ |
| You Angie | Director | D To issuer deriv | 2024-02-26 | 2024-02-27 | 40,848 | — | $0 | 0 | SEC↗ |
| You Angie | Director | D To issuer deriv | 2024-02-26 | 2024-02-27 | 73,731 | — | $0 | 0 | SEC↗ |
| Oliger Christy J. | Director | D To issuer deriv | 2024-02-26 | 2024-02-27 | 114,579 | — | $0 | 0 | SEC↗ |
| SONG KENNETH | PRESIDENT AND CHIEF EXECUTIV | D To issuer | 2024-02-26 | 2024-02-27 | 1,622,968 | $62.50 | $101.44M | 0 | SEC↗ |
| Kush Arvind | CHIEF FINANCIAL OFFICER | D To issuer | 2024-02-26 | 2024-02-27 | 78,433 | $62.50 | $4.90M | 0 | SEC↗ |
| Moran Susan | CHIEF MEDICAL OFFICER | D To issuer | 2024-02-26 | 2024-02-27 | 323,455 | $62.50 | $20.22M | 0 | SEC↗ |
| Katabi Maha | Director | D To issuer | 2024-02-26 | 2024-02-27 | 1,209,764 | $62.50 | $75.61M | 0 | SEC↗ |
| Katabi Maha | Director | D To issuer | 2024-02-26 | 2024-02-27 | 1,209,764 | $62.50 | $75.61M | 0 | SEC↗ |
| Heyman Richard A. | Director | D To issuer | 2024-02-26 | 2024-02-27 | 367,446 | $62.50 | $22.97M | 0 | SEC↗ |
| Viking Global Opportunities GP | 10% Owner | J Other | 2024-02-26 | 2024-02-28 | 1,743,556 | — | $0 | 0 | SEC↗ |
| Viking Global Opportunities GP | 10% Owner | J Other | 2024-02-26 | 2024-02-28 | 4,899,144 | — | $0 | 0 | SEC↗ |
| Ott David C. | 10% Owner | J Other | 2024-02-26 | 2024-02-28 | 4,899,144 | — | $0 | 0 | SEC↗ |
| Ott David C. | 10% Owner | J Other | 2024-02-26 | 2024-02-28 | 1,743,556 | — | $0 | 0 | SEC↗ |
| Moran Susan | CHIEF MEDICAL OFFICER | M Exercise deriv | 2024-01-22 | 2024-02-06 | 30,875 | — | $0 | 60,757 | SEC↗ |
| Moran Susan | CHIEF MEDICAL OFFICER | M Exercise | 2024-01-22 | 2024-02-06 | 30,875 | $3.24 | $100.0K | 322,647 | SEC↗ |
| Moran Susan | Chief Medical Officer | A Award deriv | 2023-11-17 | 2023-11-17 | 164,000 | — | $0 | 164,000 | SEC↗ |
| Katabi Maha | Director | A Award deriv | 2023-11-17 | 2023-11-17 | 18,235 | — | $0 | 18,235 | SEC↗ |
| SONG KENNETH | President and Chief Executiv | A Award deriv | 2023-11-17 | 2023-11-17 | 480,000 | — | $0 | 480,000 | SEC↗ |
| Kush Arvind | Chief Financial Officer | A Award deriv | 2023-11-17 | 2023-11-17 | 164,000 | — | $0 | 164,000 | SEC↗ |
| Van Hauwermeiren Timothy | Director | A Award deriv | 2023-11-01 | 2023-11-01 | 48,628 | — | $0 | 48,628 | SEC↗ |
| Wellington Biomedical Innovati | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-19 | 1,557,846 | — | $0 | 0 | SEC↗ |
| Adelman Robert J | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 216,127 | — | $0 | 0 | SEC↗ |
| Adelman Robert J | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 1,123,862 | — | $0 | 0 | SEC↗ |
| Adelman Robert J | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 3,786,957 | — | $0 | 0 | SEC↗ |
| Shabet Rose Sharon | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 864,509 | — | $0 | 0 | SEC↗ |
| Shabet Rose Sharon | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 432,254 | — | $0 | 0 | SEC↗ |
| Shabet Rose Sharon | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 2,609,392 | — | $0 | 0 | SEC↗ |
| Shabet Rose Sharon | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 1,285,223 | — | $0 | 0 | SEC↗ |
| Viking Global Opportunities Dr | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 864,509 | — | $0 | 0 | SEC↗ |
| Viking Global Opportunities Dr | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 432,254 | — | $0 | 0 | SEC↗ |
| Viking Global Opportunities Dr | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 1,285,223 | — | $0 | 0 | SEC↗ |
| Viking Global Opportunities Dr | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 2,609,392 | — | $0 | 0 | SEC↗ |
| Katabi Maha | Director | C Conversion deriv | 2023-09-19 | 2023-09-21 | 973,653 | — | $0 | 0 | SEC↗ |
| Katabi Maha | Director | C Conversion deriv | 2023-09-19 | 2023-09-21 | 973,653 | — | $0 | 0 | SEC↗ |
| Redmile Biopharma Investments | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 864,509 | — | $0 | 0 | SEC↗ |
| Redmile Biopharma Investments | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 498,510 | — | $0 | 0 | SEC↗ |
| Redmile Biopharma Investments | 10% Owner | C Conversion deriv | 2023-09-19 | 2023-09-21 | 432,254 | — | $0 | 0 | SEC↗ |
| Wellington Biomedical Innovati | 10% Owner | C Conversion | 2023-09-19 | 2023-09-19 | 1,557,846 | — | $0 | 1,557,846 | SEC↗ |
| Adelman Robert J | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 247,343 | — | $0 | 5,158,162 | SEC↗ |
| Adelman Robert J | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 1,123,862 | — | $0 | 4,910,819 | SEC↗ |
| Adelman Robert J | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 3,786,957 | — | $0 | 3,786,957 | SEC↗ |
| Shabet Rose Sharon | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 2,609,392 | — | $0 | 3,968,588 | SEC↗ |
| Shabet Rose Sharon | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 1,285,223 | — | $0 | 1,285,223 | SEC↗ |
| Shabet Rose Sharon | 10% Owner | P Buy | 2023-09-19 | 2023-09-21 | 930,556 | $18.00 | $16.75M | 4,899,144 | SEC↗ |
| Shabet Rose Sharon | 10% Owner | P Buy | 2023-09-19 | 2023-09-21 | 458,333 | $18.00 | $8.25M | 1,743,556 | SEC↗ |
| Shabet Rose Sharon | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 494,687 | — | $0 | 1,359,196 | SEC↗ |
| Shabet Rose Sharon | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 864,509 | — | $0 | 864,509 | SEC↗ |
| Viking Global Opportunities Dr | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 494,687 | — | $0 | 1,359,196 | SEC↗ |
| Viking Global Opportunities Dr | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 1,285,223 | — | $0 | 1,285,223 | SEC↗ |
| Viking Global Opportunities Dr | 10% Owner | P Buy | 2023-09-19 | 2023-09-21 | 458,333 | $18.00 | $8.25M | 1,743,556 | SEC↗ |
| Viking Global Opportunities Dr | 10% Owner | P Buy | 2023-09-19 | 2023-09-21 | 930,556 | $18.00 | $16.75M | 4,899,144 | SEC↗ |
| Viking Global Opportunities Dr | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 2,609,392 | — | $0 | 3,968,588 | SEC↗ |
| Viking Global Opportunities Dr | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 864,509 | — | $0 | 864,509 | SEC↗ |
| Katabi Maha | Director | C Conversion | 2023-09-19 | 2023-09-21 | 973,653 | — | $0 | 973,653 | SEC↗ |
| Katabi Maha | Director | P Buy | 2023-09-19 | 2023-09-21 | 236,111 | $18.00 | $4.25M | 1,209,764 | SEC↗ |
| Katabi Maha | Director | P Buy | 2023-09-19 | 2023-09-21 | 236,111 | $18.00 | $4.25M | 1,209,764 | SEC↗ |
| Katabi Maha | Director | C Conversion | 2023-09-19 | 2023-09-21 | 973,653 | — | $0 | 973,653 | SEC↗ |
| Redmile Biopharma Investments | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 864,509 | — | $0 | 864,509 | SEC↗ |
| Redmile Biopharma Investments | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 498,510 | — | $0 | 1,857,706 | SEC↗ |
| Redmile Biopharma Investments | 10% Owner | C Conversion | 2023-09-19 | 2023-09-21 | 494,687 | — | $0 | 1,359,196 | SEC↗ |